ImmunoIVD focuses on molecular assays for neonatal screening. The SPOT-it™ kit is CE marked and has been developed to facilitate population-scale screening to detect newborns with SCID, XLA and/or SMA. The company is built on a strong foundation with more than 30 years experience of successfully running a biotech company, and world renowned researchers within the field of clinical immunology and immunogenetics. Early detection increases the chances for children born with SCID, XLA and SMA to live life to its fullest. We believe all children should be given that chance.